ClinicalTrials.gg
RecruitingNCT07250789Updated Nov 26, 2025

Cognitive Screening and Multidomain Intervention Targeting Cognitive Decline in Type 2 Diabetes (The Brain Care Study)

An interventional study of Multidomain Intervention Targeting Cognitive Decline in Diabetes, Diabetes Mellitus Type 2 and Type 2 Diabetes, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 3 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2024, registered Nov 2025).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.

Planned enrollment
Largest of 24
420 · median 94
Started
2024
with 3 others
No phase
17 of 31
5 open now
Registered
26th of 31
by date

Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one has the largest planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, and was the 26th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, or all of them as a file.
02

Study summary

The purpose of The Brain Care Study is to investigate the prevalence of cognitive impairment in older adults with type 2 diabetes (T2D) and to evaluate the effectiveness of a multidomain intervention designed to prevent cognitive decline.

Read the detailed description

Type 2 diabetes (T2D) is a chronic condition associated with cognitive decline and an increased risk of Alzheimer's disease and vascular dementia. Cognitive impairment in individuals with T2D complicates disease management, often leading to poorer clinical outcomes. Although guidelines recommend cognitive screening for older adults with T2D, uncertainties remain regarding how to best identify high-risk individuals and adjust treatment strategies. While multidomain interventions have shown potential in delaying cognitive decline, further research is needed to develop feasible and effective strategies for at-risk populations.

The Brain Care Study consists of two parts: a prevalence study involving cognitive screening and a two-year randomized controlled trial (RCT) to assess a multidomain intervention targeting multiple risk factors, including pharmacological optimization, lifestyle changes, and social interaction.

The multidomain intervention focuses on optimizing medication, adjusting HbA1c targets, managing vascular risk factors, and addressing hearing impairment, depression, physical activity, and cognitive training. Additionally, the study will employ dialogue tools, text message reminders, and social interaction to enhance participants' health and adherence to the intervention.

The study hypothesizes that cognitive screening will be feasible and will not increase diabetes-related distress, while the intervention may reduce cognitive decline, improve health-related quality of life, decrease hospitalization rates, and minimize the need for home visits or relocation to nursing homes. Study endpoints include the prevalence of cognitive impairment, changes in cognitive function, hospitalization rates, and medication adherence, with the goal of providing evidence-based recommendations for future diabetes care guidelines.

Overall, the Brain Care Study aims to quantify the prevalence of cognitive decline in older individuals with type 2 diabetes and generate data to inform future guidelines for cognitive screening and interventions in this population.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus Type 2
  • Type 2 Diabetes
  • Type 2 Diabetes Mellitus (T2DM)
  • Cognitive Impairment
  • Cognitive Decline

Browse trials for

Keywords

  • diabetes
  • type 2 diabetes
  • type 2 diabetes mellitus
  • t2d
  • t2dm
  • cognitive impairment
  • cognitive decline
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 420 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for the Prevalence Study (Cognitive Screening):

  • Age ≥ 65 years
  • Diagnosis of Type 2 Diabetes (T2D)
  • Patient at the outpatient clinic at either Bispebjerg Hospital, Rigshospitalet, or Steno Diabetes Center Copenhagen
  • Speaks and understands Danish (required for the cognitive tests)
  • Informed written consent

Inclusion Criteria for the Randomized Controlled Trial (Multidomain Intervention):

  • Meets all the above inclusion criteria, and at least one of the following:

    1. A diabetes-specific dementia score ≥ 7 (equivalent to a 40% increased risk of developing dementia within the next 10 years), and a SCIP or score ≥ 0.5 SD below the age- and education-adjusted norm
    2. A SCIP or MoCA score ≥ 1 SD below the age- and education-adjusted norm
    3. At least 2 out of 5 SCIP subtests with a score ≥ 1 SD below the age- and education-adjusted norm

      Exclusion Criteria for the Prevalence Study (Cognitive Screening):

  • Diagnosis of dementia or prior referral to a dementia clinic
  • Diagnosis of psychiatric, neurological, or other disorders that, in the investigator's opinion, hinder participation in cognitive screening, preclude compliance with the study protocol, or affect the evaluation of results

Exclusion Criteria for the Randomized Controlled Trial (Multidomain Intervention):

  • Meets all the above exclusion criteria
  • Participants whose cognitive MoCA screening indicates dementia will be excluded and advised to contact their physician
  • Participants unwilling to engage in parts of the multidomain intervention will be excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Intervention

    Other: Multidomain Intervention Targeting Cognitive Decline

  • No intervention
    Usual Care

Interventions

  • OtherMultidomain Intervention Targeting Cognitive Decline

    The multidomain intervention will include the following: Optimization of pharmacological treatment/Pharmacological neuroprotection. Adjustment of HbA1c targets. Vascular risk factor management. Assessment of hearing impairment. Assessment of depression. Dialogue tools. Social interaction. Guidance on physical training. Cognitive training. Text message reminders.

07

What researchers measure

Primary outcomes

  1. Difference in Change in Cognitive Function

    Difference in change in cognitive function (visit 1 compared to follow-up) measured by SCIP between the multifactorial intervention group and the usual care group.

    Time frame: 2 years

Secondary outcomes

  1. The Number of Hospitalizations Related to All-cause Disease

    Time frame: 2 years

  2. Changes in Health-related Quality of Life Measured by SF-36

    Time frame: 2 years

08

Study locations

3 of 3 sites recruiting
  • Department of Endocrinology, Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
    • Malin S. D. Nilsson, MD, PhD · Contactmalin.nilsson@regionh.dk · +45 50 59 58 61
    • Thomas Almdal, Professor, MD, DMSc · Principal investigator
  • Department of Endocrinology, Bispebjerg-Frederiksberg Hospital
    Copenhagen, 2400, Denmark
    Recruiting
    • Malin S. D. Nilsson, MD, PhD · Contactmalin.nilsson@regionh.dk · + 45 50 59 58 61
    • Mette Zander, Associate professor, MD PhD · Principal investigator
  • Steno Diabetes Center Copenhagen
    Herlev, 2730, Denmark
    Recruiting
    • Malin S. D. Nilsson, MD, PhD · Contactmalin.nilsson@regionh.dk · +45 50 59 58 61
    • Malin S. D. Nilsson, MD, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2029, 60 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 60 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 26, 2025
StartActual
Jun 1, 2024
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07250789
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Jun 1, 2024
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 26, 2025

Study contacts

Malin S. D. Nilsson, MD, PhD
Contact
malin.nilsson@regionh.dk
+4550595861
Jørgen Rungby, Professor, MD, DMSc
study chair · Steno Diabetes Center Copenhagen
Malin S.D. Nilsson, MD, PhD
principal investigator · Steno Diabetes Center Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion